Background: Several clinical studies have indicated the efficacy of cilostazol, a selective
inhibitor of phosphodiesterase 3, in preventing cerebral vasospasm after aneurysmal …

Object Cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH) is a
major cause of subsequent morbidity and mortality. Cilostazol, a selective inhibitor of …

Previous studies with small sample size have shown that cilostazol can reduce the risk of
cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH). The …

Background: Cerebral vasospasm (VS) is the most common cause of morbidity and mortality
after aneurysmal subarachnoid hemorrhage (SAH). Reversal of VS by intra-arterial infusion …

Objectives Cilostazol, a selective inhibitor of phosphodiesterase 3, may reduce symptomatic
vasospasm and improve outcome in patients with aneurysmal subarachnoid hemorrhage …

Objective Cerebral vasospasm is a common complication after aneurysmal subarachnoid
hemorrhage (aSAH). Many drugs have been tried to mitigate cerebral vasospasm and …

Abstract Background and Purpose: Delayed cerebral ischemia is a major cause of morbidity
and mortality in patients with aneurysmal subarachnoid hemorrhage (aSAH). Cilostazol, a …

Cerebral vasospasm is the classic cause of delayed neurological deterioration leading to
cerebral ischemia and infarction, and thus, poor outcome and occasionally death, after …

Cilostazol is an antiplatelet aggregation inhibitor drug associated with increased cerebral
blood flow and inflammation suppression. This study evaluated administration of cilostazol …

Objectives To examine the clinical outcome of aneurysmal subarachnoid haemorrhage
(aSAH) patients exposed to cerebral vasospasm (CVS)-targeted treatments in a meta …